Hepatocellular Carcinoma Drugs Market is expected to reach US$ 1.82 Bn. at a CAGR of 7.7% during the forecast period 2029. Hepatocellular carcinoma (HCC) is the most widely recognized essential liver malignancy, representing 75% to 80% of liver malignant growths around the world. It is one of the causes of cancer-related deaths globally. Excessive liquor intake causes liver cirrhosis, viral contaminations, for example, hepatitis B and C, and lifestyle problems are significant risk factors related to the advancement of hepatocellular carcinoma. Hepatocellular carcinoma drugs are utilized to treat such dangerous issues. Sorafenib, nivolumab, regorafenib, lenvatinib, cabozantinib, and pembrolizumab are the recent accessible medications for patients with advanced HCC.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Rise in the occurrence of hepatocellular carcinoma and increase in mortality related with liver cancer globally are the major factors driving the hepatocellular carcinoma drugs market. As per the American Cancer Society, almost 42,030 new patients were estimated to have liver cancer in the U.S. in 2019: out of these, three-fourths HCC. Thus, around 31,780 liver cancer deaths were assessed to happen in 2019 in the U.S. Changing lifestyle, weight, hypertension, diabetes, and increase in the aged patient population are different variables forecasted to increase the growth of the global hepatocellular carcinoma drugs market during the forecast period. North American region is expected to account for the largest xx% Hepatocellular Carcinoma Drugs Market share by 2029. The rising prevalence of the disease, emerging number of clinical trials embraced by the producers to address the unmet clinical needs of the patients in the region. As indicated by the survey of Health Science Department, University of California, Los Angeles, (UCLA), 2022, hepatocellular carcinoma (HCC) represents 75% of liver cancer in the U.S. with an expected 40,000 Americans identified to have liver cancer in 2022 and in excess of 28,000 passing are accounted for from the ailment. The Asia Pacific is expected to gain significant growth globally in hepatocellular carcinoma drugs market owing to the developing number of research and development activities attempted by the companies in the region so as to create effective treatments for the treatment of Hepatocellular carcinoma. For example, in February 2022, Daiichi Sankyo, a pharma organization in Japan finished the Phase-3 study of tivantinib showed for patients with hepatocellular carcinoma treated with different treatments. The objective of the report is to present a comprehensive analysis of the Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Market dynamics, structure by analyzing the market segments and projects the Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Market make the report investor’s guide.
Hepatocellular Carcinoma Drugs Market Scope: Inquire before buying
Global Hepatocellular Carcinoma Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 1.08 Bn. Forecast Period 2023 to 2029 CAGR: 7.7% Market Size in 2029: US $ 1.82 Bn. Segments Covered: by Drug Class Tyrosine kinase inhibitors PD-1/PD-L1 inhibitors. by End User Hospitals Clinics Cancer rehabilitation centers Ambulatory surgical centers Others Hepatocellular Carcinoma Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Hepatocellular Carcinoma Drugs Market, Key Players are
1.Novartis Pharmaceuticals 2. Bayer AG 3. Merck & Co. 4. Bristol-Myers Squibb Company 5. AbbVie Inc. 6. Johnson & Johnson 7. Celgen Corporation 8. Amgen Inc. 9. Teva Pharmaceutical Industries Ltd. 10. Pfizer Inc. 11. Takeda Pharmaceutical Co. Ltd 12. Eisai 13. Merck Co. & Inc. 14. Eli Lilly 15. Others Frequently Asked Questions: 1. Which region has the largest share in Global Hepatocellular Carcinoma Drugs Market? Ans: Asia Pacific region holds the highest share in 2022. 2. What is the growth rate of Global Hepatocellular Carcinoma Drugs Market? Ans: The Global Hepatocellular Carcinoma Drugs Market is growing at a CAGR of 7.7% during forecasting period 2023-2029. 3. What is scope of the Global Hepatocellular Carcinoma Drugs market report? Ans: Global Hepatocellular Carcinoma Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Hepatocellular Carcinoma Drugs market? Ans: The important key players in the Global Hepatocellular Carcinoma Drugs Market are – Novartis Pharmaceuticals, Bayer AG, Merck & Co., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd, Eisai, Merck Co. & Inc., Eli Lilly, and Others 5. What is the study period of this market? Ans: The Global Hepatocellular Carcinoma Drugs Market is studied from 2022 to 2029.
1. Hepatocellular Carcinoma Drugs Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Hepatocellular Carcinoma Drugs Market: Dynamics 2.1. Hepatocellular Carcinoma Drugs Market Trends by Region 2.1.1. North America Hepatocellular Carcinoma Drugs Market Trends 2.1.2. Europe Hepatocellular Carcinoma Drugs Market Trends 2.1.3. Asia Pacific Hepatocellular Carcinoma Drugs Market Trends 2.1.4. Middle East and Africa Hepatocellular Carcinoma Drugs Market Trends 2.1.5. South America Hepatocellular Carcinoma Drugs Market Trends 2.2. Hepatocellular Carcinoma Drugs Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Hepatocellular Carcinoma Drugs Market Drivers 2.2.1.2. North America Hepatocellular Carcinoma Drugs Market Restraints 2.2.1.3. North America Hepatocellular Carcinoma Drugs Market Opportunities 2.2.1.4. North America Hepatocellular Carcinoma Drugs Market Challenges 2.2.2. Europe 2.2.2.1. Europe Hepatocellular Carcinoma Drugs Market Drivers 2.2.2.2. Europe Hepatocellular Carcinoma Drugs Market Restraints 2.2.2.3. Europe Hepatocellular Carcinoma Drugs Market Opportunities 2.2.2.4. Europe Hepatocellular Carcinoma Drugs Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Hepatocellular Carcinoma Drugs Market Drivers 2.2.3.2. Asia Pacific Hepatocellular Carcinoma Drugs Market Restraints 2.2.3.3. Asia Pacific Hepatocellular Carcinoma Drugs Market Opportunities 2.2.3.4. Asia Pacific Hepatocellular Carcinoma Drugs Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Hepatocellular Carcinoma Drugs Market Drivers 2.2.4.2. Middle East and Africa Hepatocellular Carcinoma Drugs Market Restraints 2.2.4.3. Middle East and Africa Hepatocellular Carcinoma Drugs Market Opportunities 2.2.4.4. Middle East and Africa Hepatocellular Carcinoma Drugs Market Challenges 2.2.5. South America 2.2.5.1. South America Hepatocellular Carcinoma Drugs Market Drivers 2.2.5.2. South America Hepatocellular Carcinoma Drugs Market Restraints 2.2.5.3. South America Hepatocellular Carcinoma Drugs Market Opportunities 2.2.5.4. South America Hepatocellular Carcinoma Drugs Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Hepatocellular Carcinoma Drugs Industry 2.8. Analysis of Government Schemes and Initiatives For Hepatocellular Carcinoma Drugs Industry 2.9. Hepatocellular Carcinoma Drugs Market Trade Analysis 2.10. The Global Pandemic Impact on Hepatocellular Carcinoma Drugs Market 3. Hepatocellular Carcinoma Drugs Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 3.1.1. Tyrosine kinase inhibitors 3.1.2. PD-1/PD-L1 inhibitors 3.2. Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 3.2.1. Hospitals 3.2.2. Clinics 3.2.3. Cancer rehabilitation centers 3.2.4. Ambulatory surgical centers 3.2.5. Others 3.3. Hepatocellular Carcinoma Drugs Market Size and Forecast, by Region (2022-2029) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America Hepatocellular Carcinoma Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.1.1. Tyrosine kinase inhibitors 4.1.2. PD-1/PD-L1 inhibitors 4.2. North America Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 4.2.1. Hospitals 4.2.2. Clinics 4.2.3. Cancer rehabilitation centers 4.2.4. Ambulatory surgical centers 4.2.5. Others 4.3. North America Hepatocellular Carcinoma Drugs Market Size and Forecast, by Country (2022-2029) 4.3.1. United States 4.3.1.1. United States Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.3.1.1.1. Tyrosine kinase inhibitors 4.3.1.1.2. PD-1/PD-L1 inhibitors 4.3.1.2. United States Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 4.3.1.2.1. Hospitals 4.3.1.2.2. Clinics 4.3.1.2.3. Cancer rehabilitation centers 4.3.1.2.4. Ambulatory surgical centers 4.3.1.2.5. Others 4.3.2. Canada 4.3.2.1. Canada Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.3.2.1.1. Tyrosine kinase inhibitors 4.3.2.1.2. PD-1/PD-L1 inhibitors 4.3.2.2. Canada Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 4.3.2.2.1. Hospitals 4.3.2.2.2. Clinics 4.3.2.2.3. Cancer rehabilitation centers 4.3.2.2.4. Ambulatory surgical centers 4.3.2.2.5. Others 4.3.3. Mexico 4.3.3.1. Mexico Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.3.3.1.1. Tyrosine kinase inhibitors 4.3.3.1.2. PD-1/PD-L1 inhibitors 4.3.3.2. Mexico Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 4.3.3.2.1. Hospitals 4.3.3.2.2. Clinics 4.3.3.2.3. Cancer rehabilitation centers 4.3.3.2.4. Ambulatory surgical centers 4.3.3.2.5. Others 5. Europe Hepatocellular Carcinoma Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.2. Europe Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3. Europe Hepatocellular Carcinoma Drugs Market Size and Forecast, by Country (2022-2029) 5.3.1. United Kingdom 5.3.1.1. United Kingdom Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.1.2. United Kingdom Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.2. France 5.3.2.1. France Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.2.2. France Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.3. Germany 5.3.3.1. Germany Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.3.2. Germany Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.4. Italy 5.3.4.1. Italy Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.4.2. Italy Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.5. Spain 5.3.5.1. Spain Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.5.2. Spain Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.6. Sweden 5.3.6.1. Sweden Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.6.2. Sweden Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.7. Austria 5.3.7.1. Austria Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.7.2. Austria Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.3.8.2. Rest of Europe Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6. Asia Pacific Hepatocellular Carcinoma Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.2. Asia Pacific Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3. Asia Pacific Hepatocellular Carcinoma Drugs Market Size and Forecast, by Country (2022-2029) 6.3.1. China 6.3.1.1. China Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.1.2. China Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.2. S Korea 6.3.2.1. S Korea Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.2.2. S Korea Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.3. Japan 6.3.3.1. Japan Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.3.2. Japan Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.4. India 6.3.4.1. India Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.4.2. India Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.5. Australia 6.3.5.1. Australia Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.5.2. Australia Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.6. Indonesia 6.3.6.1. Indonesia Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.6.2. Indonesia Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.7. Malaysia 6.3.7.1. Malaysia Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.7.2. Malaysia Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.8. Vietnam 6.3.8.1. Vietnam Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.8.2. Vietnam Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.9. Taiwan 6.3.9.1. Taiwan Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.9.2. Taiwan Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.3.10.2. Rest of Asia Pacific Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 7. Middle East and Africa Hepatocellular Carcinoma Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.2. Middle East and Africa Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 7.3. Middle East and Africa Hepatocellular Carcinoma Drugs Market Size and Forecast, by Country (2022-2029) 7.3.1. South Africa 7.3.1.1. South Africa Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.3.1.2. South Africa Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 7.3.2. GCC 7.3.2.1. GCC Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.3.2.2. GCC Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 7.3.3. Nigeria 7.3.3.1. Nigeria Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.3.3.2. Nigeria Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.3.4.2. Rest of ME&A Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 8. South America Hepatocellular Carcinoma Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.2. South America Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 8.3. South America Hepatocellular Carcinoma Drugs Market Size and Forecast, by Country (2022-2029) 8.3.1. Brazil 8.3.1.1. Brazil Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.3.1.2. Brazil Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 8.3.2. Argentina 8.3.2.1. Argentina Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.3.2.2. Argentina Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America Hepatocellular Carcinoma Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.3.3.2. Rest Of South America Hepatocellular Carcinoma Drugs Market Size and Forecast, by End User (2022-2029) 9. Global Hepatocellular Carcinoma Drugs Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Hepatocellular Carcinoma Drugs Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Novartis Pharmaceuticals 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Bayer AG 10.3. Merck & Co. 10.4. Bristol-Myers Squibb Company 10.5. AbbVie Inc. 10.6. Johnson & Johnson 10.7. Celgen Corporation 10.8. Amgen Inc. 10.9. Teva Pharmaceutical Industries Ltd. 10.10. Pfizer Inc. 10.11. Takeda Pharmaceutical Co. Ltd 10.12. Eisai 10.13. Merck Co. & Inc. 10.14. Eli Lilly 10.15. Others 11. Key Findings 12. Industry Recommendations 13. Hepatocellular Carcinoma Drugs Market: Research Methodology 14. Terms and Glossary